OGNCongressional Stock Trades
Organon & Co.
Pharmaceutical Preparations
Congressional stock trades in Organon & Co. (OGN) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
2
Politicians Trading
2
Last Traded
Aug 5, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Kevin HernR | Aug 10, 2026 | Aug 5, 2026 | Sell | $1,001 - $15,000 | +2.06% |
| Gary C. PetersD | Nov 24, 2025 | Jul 10, 2025 | Sell | $1,001 - $15,000 | +38.22% |
Price History
About Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
2 members of Congress have disclosed 2 trades in Organon & Co. (OGN). Most active: Gary C. Peters (1), Kevin Hern (1).
Across all disclosures, members of Congress reported 0 purchases and 2 sales of Organon & Co. (OGN). The most recent trade was on Aug 5, 2026.
Kevin Hern disclosed selling Organon & Co. (OGN) on Aug 5, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.